OR WAIT null SECS
The breakthrough approach is commonly used, but the devil is in the details.
In this article, a simple chromatographic model is proposed that is capable of predicting the impact of pH and ionic strength on HIC chromatograms.
The COVID-19 vaccines opened the door to powerful market potential for other nucleic acid-based therapies.
The innovation of going from stainless-steel bioreactors to fixed-bed bioreactors shows an evolution in upstream optimization.
Makers of specialty biologics, gene therapies, and other personalized medicines are working to identify and reduce potential supply chain risks both upstream and downstream.
FDA has spurred investment to create and develop 600 therapies.
What can we take away from Pfizer's acquisition of Seagen?
June 06, 2023
invoX Pharma has made a second tranche of investment in pHion Therapeutics to support further development of next-generation mRNA vaccines.
Lonza will gain access to R&D capabilities, including payload and site-specific linker technology, through its acquisition of ADC company, Synaffix.
June 05, 2023
Adamis Pharmaceuticals announced the closing of its merger with DMK Pharmaceuticals on May 25, 2023.
Reimbursement for Alzheimer's medicines still will occur only with the completion of studies to support full FDA approval.
Paxlovid is not approved or authorized for use as a pre-exposure or post-exposure prophylaxis for prevention of COVID-19.
FDA has published a new system for providing basic and essential information on patient use of drugs and certain biologic products.
June 02, 2023
Hope is on the horizon as novel solutions and improvements aimed at benefitting the drug development process with the right framework are coming to the fore.
New fields are being explored to bring novel antibody candidates to the pipeline.
Compliance with GMP standards remains an integral focus in bulk mAb manufacturing.
June 01, 2023
Scaling cell therapy production workflows requires the establishment of closed, automated steps.
Analytical characterization of biosimilars plays a crucial role in a successful path to regulatory approval.
Through the acquisition, Avacta gains Coris’ product portfolio consisting of diagnostic tests for respiratory, gastroenteric, and blood-borne pathogens as well as for the detection of antibiotic resistance markers.